Resistance to new anti-HIV agents: Problems in the pathway of drug registration

Antiviral Therapy

Volumn 10, Issue 7, 2005, Pages 867-872

  Dalmau, David ^a,b   Klimkait, Thomas ^c   Telenti, Amalio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REGISTRATION; TREATMENT FAILURE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; EUROPEAN UNION; HUMAN IMMUNODEFICIENCY VIRUS 1; INFORMATION PROCESSING; METHODOLOGY; MULTIDRUG RESISTANCE; QUESTIONNAIRE; UNITED STATES; VIROLOGY;

ANTI-HIV AGENTS; CLINICAL TRIALS; DATA COLLECTION; DRUG APPROVAL; DRUG RESISTANCE, MULTIPLE, VIRAL; EUROPEAN UNION; HIV INFECTIONS; HIV-1; HUMANS; QUESTIONNAIRES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 27844600612     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Flieger, K. FDA finds new ways to speed treatments to patients. U.S. Food and Drug Administration Consumer Special Report. Washington: U.S. Food and Drug Administration; 1995 [cited 2005, September 21]. Available from: http://www.fda.gov/fdac/special/newdrug/speeding.html.
2. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Douglas D & Richman DD. Update of the drug resistance mutations in HIV-1: 2004. Topics in HIV Medicine 2004; 12:119-124.
3. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
4. Vandamme AM, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vézinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N & Hor A. Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Therapy 2004; 9:829-848.
5. Gilead Sciences Inc. Proposed package insert for Viread tablets - version 13 [monograph on the Internet]. Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2001 [cited 2005, September 21]. Available from: http://www.fda.gov/cder/foi/label/2001/21356lbl.pdf.
6. U.S. Food and Drug Administration. Approval history, Viread, NDA 21-356 [monograph on the Internet]. Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2001 [cited 2005, September 21]. Available from: http://www.fda.gov/cder/foi/appletter/2001/21356ltr.pdf.
7. Farthing C, Khanlou H & Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment of naive HIV-infected patients. Antiviral Therapy 2003, 8(Suppl 1), S195.
8. GlaxoSmithKline. Important drug warning - Early virological non-response in patients with HIV infection treated with lamivudine, abacavir and tenofovir. Pittsburgh: GlaxoSmithKline; 2003 [cited 2005, September 21]. Available from: http://aahivm.org/new/dear_doc_7-25-03.htm.
9. Gilead Sciences Inc. Important drug warning - High rate of virologic failure in patients with HIV infection treated with a once daily triple NRTI regiment containing didanosine, lamivudine and tenofovir. Foster City: Gilead Sciences Inc; 2003 [cited 2005, September 21]. Available from: http://aahivm.org/new/gilead_letter.pdf.
10. Gilead Sciences Inc. Viread label, revision NDA 21-356/S-010. Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2004 [cited 2005, September 21]. Available from: http://www.fda.gov/cder/foi/label/ 2004/21356slr010_vire ad_lbl.pdf.
11. Hill AM & Telenti A. HIV susceptibility testing - time for standards. Antiviral Therapy 2004; 9:463-464.
12. U.S. Food and Drug Administration. Guidance for industry: Antiviral drug development - conducting virologic studies. Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2005 [cited 2005, September 21]. Available from: http://www.fda.gov/cder/guidance/6568dft.htm.
13. Okie S. What ails the FDA? The New England Journal of Medicine 2005; 352:1063-1066.
14. Food and Drug Administration. Report on the performance of drug and biological firms in conducting postmarketing commitment studies; availability. Federal Register 2004; 69:12162-12164.
15. European Federation of Pharmaceutical Industry Associations, International Federation of Pharmaceutical Manufacturers and Associations, Japanese Pharmaceutical Manufacturers Associations, and Pharmaceutical Research and Manufacturers of America. Joint position on the disclosure of clinical trial information via clinical trial registries and databases. Brussles: European Federation of Pharmaceutical Industry Associations; 2005 [cited 2005, September 21]. Available from: http://www.efpia.org/4_pos/sci_regu/Clinicaltrials2005.pdf.
16. Kim EY, Vrang L, Oberg B & Merigan TC. Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. AIDS Research and Human Retroviruses 2001; 17:401-407.
17. Katlama C, Ghosn J, Tubiana R, Wirden M, Valantin MA, Harmenberg J, Mardh G, Oberg B & Calvez V. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study. AIDS 2004; 18:1299-1304.
18. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N & Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proceedings of the National Academy of Sciences of the United States of America 2003; 100:11013-11018.
19. Fujiwara T, Sato A, el-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen LB, Harada H, Sugimoto H, Hatanaka M & Hinuma Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 1998; 42:1340-1345.
20. Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW, Andries K, de Bethune MP, Azijn H, Pauwels R, Lewi PJ, Heeres J, Koymans LM, de Jonge MR, Van Aken KJ, Daeyaert FF, Das K, Arnold E & Janssen PA. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorganic and Medicinal Chemistry Letters 2001; 11:2235-2239.
21. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R & de Bethune MP. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 2004; 48:4680-4686.
22. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J & vant' Klooster GA. An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17:F49-F54.
23. Richar N, Quan Y, Salomon H, Hsu M, Bedard J, Harrigan PR & Rando R, Mansour T, Bowlin TL, Wainberg MA. Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′- oxa-4′-thiocytidine (dOTC). Antiviral Therapy 1999; 4:171-177.
24. Richard N, Salomon H, Rando R, Mansour T, Bowlin TL & Wainberg MA. Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa- 4′-thio-5-fluorocytidine. Antimicrobial Agents and Chemotherapy 2000; 44:1127-1131.
25. Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL & Rando RF. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antimicrobial Agents and Chemotherapy 2000; 11:291-301.
26. Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R, Klabe R, Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, Otto MJ, Stuyver L, Trainor G, Liotta DC & Erickson-Viitanen S. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrobial Agents and Chemotherapy 2002; 46:1394-1401.
27. Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF & Erickson-Viitanen S. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor β-D-2′,3′- dideoxy-2′,3′-didehydro-5-fluorocytidine (Reverset). Antiviral Chemistry and Chemotherapy 2003; 14:49-59.
28. Schinazi RF, Schlueter-Wirtz S & Stuyver L. Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. Antiviral Chemistry and Chemotherapy 2001; 12(Suppl 1):61-65.
29. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK & Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy 2003; 47:3123-3129.
30. Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Gulnik SV, Erickson JW & Mitsuya H. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. Journal of Virology 2002; 76:1349-1358.
31. Poppe SM, Slade DE, Chong KT, Hinshaw RR, Pagano PJ, Markowitz M, Ho DD, Mo H, Gorman RR 3rd, Dueweke TJ, Thaisrivongs S & Tarpley WG. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrobial Agents and Chemotherapy 1997; 41:1058-1063.
32. Back NK, van Wijk A, Remmerswaal D, van Monfort M, Nijhuis M, Schuurman R & Boucher CA. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 2000; 14:101-102.
33. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M & d'Arminio-Monforte A. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrobial Agents and Chemotherapy 2000; 44:1328-1332.
34. Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW & Tarpley G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14:1943-1948.
35. Bulgheroni E, Citterio P, Croce F, Lo Cicero M, Vigano O, Soster F, Chou TC, Galli M & Rusconi S. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. The Journal of Antimicrobial Chemotherapy 2004; 53:464-468.
36. Srinivas RV & Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrobial Agents and Chemotherapy 1998; 42:1484-1487.
37. Van Rompay KK, Cherrington JM, Marthas ML, Lamy PD, Dailey PJ, Canfield DR, Tarara RP, Bischofberger N & Pedersen NC. 9-[2-(Phosphonomethoxy)propyl] adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrobial Agents and Chemotherapy 1999; 43:802-812.
38. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4:87-94.
39. Miller MD, Margot NA, Hertogs K, Larder B & Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides, Nucleotides and Nucleic Acids 2001; 20:1025-1028.
40. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Jr & Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Research and Human Retroviruses 2001; 17:1167-1173.